Evidence map›Paper›PMID 26914709›Full record

ArticlePloS one2016

Club Cell-16 and RelB as Novel Determinants of Arterial Stiffness in Exacerbating COPD Patients.

Laura E Labonté, Jean Bourbeau, Stella S Daskalopoulou, Michele Zhang, Patrick Coulombe, Katie Garland, Carolyn J Baglole

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Insights into Chronic Obstructive Pulmonary Disease as Critical Risk Factor for Cardiovascular Disease.International journal of chronic obstructive pulmonary disease · 2020
    Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Laura E LabontéDepartment of Medicine, McGill University, Montreal, Quebec, Canada.
Jean BourbeauDepartment of Medicine, McGill University, Montreal, Quebec, Canada.
Stella S DaskalopoulouDepartment of Medicine, McGill University, Montreal, Quebec, Canada.
Michele ZhangRespiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Center, Montreal, Québec, Canada.
Patrick CoulombeRespiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Center, Montreal, Québec, Canada.
Katie GarlandRespiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Center, Montreal, Québec, Canada.
Carolyn J BagloleDepartment of Medicine, McGill University, Montreal, Quebec, Canada.
McGill University Health Centre · CAMcGill University · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

backgroundExacerbations of chronic obstructive pulmonary disease (COPD) are acute events of worsened respiratory symptoms that may increase the risk of cardiovascular disease (CVD), a leading cause of mortality amongst COPD patients. The utility of lung-specific inflammatory mediators such as club cell protein-16 (CC-16) and surfactant protein D (SPD) and that of a novel marker of CV outcomes in COPD- RelB- in predicting adverse cardiovascular events during exacerbation is not known.

methodsThirty-eight subjects with COPD admitted to the hospital for severe exacerbation were included in this analysis. Clinical, physiological and arterial stiffness measurements were performed within 72 hours of admission; this was followed by measurements taken every 3 days until hospital discharge, then once a week until 30 days after discharge, and then again at 90 and 180 days. Plasma concentrations of inflammatory mediators were measured from peripheral venous blood taken at admission, and at days 15, 30, 90 and 180.

resultsCC-16 and RelB concentrations were increased at day 15 of exacerbations whereas SPD concentrations were decreased. The course of change in CC-16 and RelB levels over time was inversely associated with that of carotid-femoral pulse wave velocity, the gold-standard measure of arterial stiffness. Increases in CC-16 could predict a decreased number of subsequent exacerbations during follow-up.

conclusionsLung-specific (CC-16) and novel (RelB) biomarkers are associated with systemic cardiovascular changes over time. CC-16 can predict subsequent exacerbations in subjects with severe COPD and may be an important biomarker of pulmonary and systemic stress in COPD.

Indexed as

Vascular StiffnessAgedBiomarkersDisease ProgressionFemaleHumansLungMalePulmonary Disease, Chronic ObstructivePulmonary Surfactant-Associated Protein DPulse Wave AnalysisTranscription Factor RelBUteroglobinBiomarkersPulmonary Surfactant-Associated Protein DRELB protein, humanSCGB1A1 protein, humanTranscription Factor RelBUteroglobin

Identifiers

PMID26914709
PMCPMC4767820
OpenAlexW2290759024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.